To,

November 15, 2025

National Stock Exchange of India Ltd.
Exchange Plaza,
Bandra Kurla Complex,
Bandra (E),
Mumbai- 400051

Script Name: MAITREYA

ISIN: INE0PLQ01011

Sub: Outcome of the Board Meeting held on Friday, 14th November, 2025

Dear Sir/Madam,

The Board of Directors of the Company at their meeting held today i.e. November 14, 2025, inter-alia considered and approved the following.:

1. Consider and approved the standalone and Consolidated unaudited financial results / Accounts of the Company for the Half year ended on September 30, 2025, along with the Limited Review Report:

The aforesaid Board Meeting commenced at 10:50 p.m. (IST) and concluded at 11:35 p.m. (IST).

We request you to kindly take the above on record.

Thanking You,

Yours faithfully,

For **Maitreya Medicare Limited**

SURANA KASHISH
Digitally signed by SURANA KASHISH
Date: 2025.11.15 18:21:54 +05'30'

Kashish Surana
Company Secretary & Compliance Officer

Saherwala & Co.
CHARTERED ACCOUNTANTS

Member of:
ACURA
& Affiliates
Approved CA Network
Presence in :-
Bengaluru, Delhi, Mumbai, Chennai, Kolkata, Pune, Hyderabad, Patna, Mysuru, Khagaria, Belgavi, Tirupur, Jaipur, Kurnool, **Surat,** Ahmedabad, Vellore & Burdwan

Independent Auditors' Review Report on Half Year and Year To Date Standalone Unaudited Financial Results of Maitreya Medicare Limited (Formerly Known as Maitreya Medicare Private Limited) pursuant to the Regulation 33 Of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

Review Report
To the Board of Directors of
Maitreya Medicare Limited
(Formerly Known as Maitreya Medicare Private Limited)

1. We have reviewed the accompanying statement of standalone unaudited financial results of **Maitreya Medicare Limited (Formerly Known as "Maitreya Medicare Private Limited")** (the "Company") for the Half Year ended September 30, 2025 and the year to date results for the period April 1, 2025 to September 30, 2025, ("the Statement ") being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

2. This statement is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard 25 Interim Financial Reporting, prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'). Our responsibility is to issue a report on these financial statements based on our review.

3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. 'This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatements. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

SAHERWALA & CO. SURAT Chartered Accountants

1/98, Golandaz Street, Nanpura, Surat - 395 001.
Ph. : (0261) 2472398, 2470084 Mob. : 93273 33227, Email : saherwalaca@yahoo.co.in, contact@saherwala.com
www.saherwala.com

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of standalone unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **Saherwala & Co**
Chartered Accountants
FRN - 108969W



(CA Esmayeel O. Saherwala)
Partner
Membership No. – 122386
UDIN - 25122386BMNXMC3175

Surat, November 14, 2025

MAITREYA MEDICARE LIMITED

(Formerly known as MAITREYA MEDICARE PRIVATE LIMITED)

UN AUDITED BALANCE SHEET AS ON 30th September 2025

CIN No. - U24290GJ2019PTC107298

(Currency: Rs in '000')

Particulars	Note No.	As at 30th September 2025	As at 31st March 2025
I. EQUITY & LIABILITIES			
(1) Shareholders"s Funds			
a) Share capital	1	115523	120923
b) Reserve & Surplus	2	201314	199841
c) Money received against share warrants			
(2) Share application money pending allotment			
(3) Non-Current Liabilities			
a) Long-term Borrowings	3	12431	19594
b)Deffered tax liability (Net)	4	7111	6953
c)Other long term Liabilities			
d)Long term Provisions			
(4) Current Liabilities			
a) Short-term Borrowings	5	14634	15744
b) Trade payables			
(A) total outstanding dues of micro enterprises and small enterprises; and	6		2876
(B) total outstanding dues of creditors other than micro enterprises and small enterprises.		31962	24937
c) Other curent Liabilites	7	64850	45193
d) Short term Provisions	8	8649	8075
Total		456474	444136
II. Assets			
(1) Non-current assets			
(a) Property, Plant and Equipment and Intangible Assets			
(i) Property, Plant and Equipment	9	114506	118212
(ii) Intangible Assets		1297	1445
b) Non Current Investments	10	75730	75830
c) Deffered tax asset (net)			
d) Long term loans and advances	11	66683	52238
e) Other Non current assets	12	13096	12722
(2) Current assets			
a) Current Investments	13	422	422
b) Inventories	14	6862	4798
c) Trade receivables	15	140202	151850
d) Cash & Cash equivalents	16	29586	19090
e) Short-term loans and advances	17	4196	5019
f) Other current assets	18	3895	2510
Total		456474	444136

For MAITREYA MEDICARE LIMITED

MAITREYA MEDICARE LIMITED SURAT

NARENDRA TANWAR

DIN - 0008459007

MD AND CFO

14th Nov 2025, Surat.

Maitreya Medicare Limited
(Formerly known as "Maitreya Medicare Private Limited")

CIN - U24290GJ2019PLC107298

STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE HALF YEAR ENDED SEPTEMBER 30, 2025

	Particulars	Half year ended		For the year ended March 31, 2025	For the year ended March 31, 2024
		September 30, 2025	September 30, 2024		
		Unaudited	Unaudited	Audited	Audited
I	Revenue from operations	2,327.80	2,217.98	4,441.32	4,652.81
II	Other income	14.09	14.28	43.98	22.27
III	Total Revenue (I + II)	2,341.89	2,232.26	4,485.30	4,675.08
IV	**Expenses:**				
	(a) Cost of Raw Material Consumed	213.65	159.07	286.80	375.49
	(b) Purchase of Stock-in-Trade	257.92	260.63	586.29	546.77
	(c) Changes in inventories of stock-in-trade	-0.15	0.61	(1.03)	26.64
	(d) Employee benefits expense	250.47	243.55	521.88	475.19
	(e) Finance costs	36.74	38.35	75.44	73.90
	(f) Depreciation and amortization expense	71.47	63.46	134.59	125.59
	(g) Other expenses	1,489.76	1,281.08	2,559.09	2,612.66
	Total Expenses	2,319.86	2,046.75	4,163.06	4,236.24
V	**Profit before prior-period items and tax (III - IV)**	22.03	185.51	322.25	438.85
VI	Prior-Period Items		-		-
VII	Profit before tax (V- VI)	22.03	185.51	322.25	438.85
VIII	Tax expense:				
	(1) Current tax expense	5.73	49.77	80.75	119.94
	(2) Deferred tax expense/(credit)	1.58	1.13	1.13	1.53
	(3) Short/(Excess) provision of tax for earlier years		-	50.42	-
	Dividend on Preference Shares	7.31	50.90	132.29	121.46
IX	**Profit from continuing operations (VII-VIII)**	14.72	134.61	189.96	317.39
X	Paid-up Equity Share Capital (Face Value of ₹ 10/- each)	677.60	677.60	677.60	677.60
XI	Reserves excluding revaluation reserves as per balance sheet of previous accounting year		-		
XII	Earnings per Equity Share (Non-Annualised) :- Face Value of ₹ 10/- each				
	(Pre-bonus)				
	- Basic				
	- Diluted				
	(Post-bonus)				
	- Basic				
	- Diluted				

For MAITREYA MEDICARE LIMITED

MAITREYA MEDICARE LIMITED SURAT

NARENDRA TANWAR
DIN - 0008459007
Managing Director & CFO

Place : Surat
Date : 14/11/2025

MAITREYA MEDICARE LIMITED
(Formerly known as MAITREYA MEDICARE PRIVATE LIMITED)
UN AUDITED PROFIT AND LOSS STATEMENT FOR THE PERIOD ENDED ON 30th September 2025
CIN No. - U24290GJ2019PTC107298
(Currency: Rs in '000')

Particulars	Note No.	As at 30th September 2025	As at 31st March 2025
I. Revenue from operations	19	232780	444132
II. Other Income	20	1409	4398
III. Total Income (I+II)		234189	448530
IV, Expenses:			
Consumption of Stores and Pharmacy	21	21365	28680
Purchase of stock-in-Trade	22	25792	58629
Changes in inventories of finished goods, work-in-progress and stock-in-Trade	23	-15	-103
Employee benefit expense	24	25047	52188
Financial Costs	25	3674	7544
Depreciation and amortization expense	26	7147	13459
Other expense	27	148976	255909
Total Expense		231985	416306
V.Profit Before exceptional and extradinary items and tax	(III-IV)	2204	32224
VI. Exceptional Items			
Adjustment of GST Liability			
Reversal of Previous Year Income Tax/TCS			
Rectification of Previous Year Mutual Fund Value			
Rectification of Depreciation			
Gratuity Prior Period			
Operating lease Prior Period Adjustment			
VII. Profit Before extraorinary items and tax (V-VI)		2204	32224
VIII. Extraordinary Items			
IX. Profit before tax (VII-VIII)		2204	32224
X. Tax expense:			
(1) Current Tax	28	573	8075
(2) Deferred Tax	29	158	113
(3) MAT Credit Entitlement			
(4) Income Tax Paid 2023-2024			5042
XI. Profit(Loss) from the period from continuing operations		1473	18993
XII. Profit/(Loss) from discontinuing operations			
XIII. Tax expense of discontinuing operations			
XIV. Profit/(Loss) from discountinuing operations (XII- XIII)			
XV. Profit/Loss for the period (XI+XIV)		1473	18993
XVI. Earning per equity share:	30		
Basic		0.22	2.80
Diluted		0.22	2.80

For MAITREYA MEDICARE LIMITED

MAITREYA MEDICARE LIMITED SURAT

NARENDRA TANWAR
DIN - 0008459007
MD AND CFO
14th Nov 2025, Surat.

MAITREYA MEDICARE LIMITED
(Formerly known as MAITREYA MEDICARE PRIVATE LIMITED)
UN AUDITED CASH FLOW STATEMENT
CIN No. - U24290GJ2019PTC107298
(Currency: Rs in '000')

PARTICULARS		As at 30th September 2025		As at 31st March 2025	
A. Cash Flow from Operating Activities:					
Profit Before exceptional and extradinary items and tax			2204339		32224466
Adjustments for :					
Depreciation		7146971		13459317	
Interest Income		-337714		-694517	
Gratuity		439904		1676588	
Interest & Finance Charges Paid		3674362		7544390	
Profit on sale of Investment		0		-225088	
Sundry Balance Write back		244308		0	
Operating Profit before Working Capital Changes			11167831		21760690
Adjustments for :			13372171		53985155
Increase / Decrease in Inventories		-2063817		-112604	
Increase / Decrease in Short-term loans and advances		823769		-3478366	
Increase / Decrease in Trade Receivables		11403293		-21142190	
Increase / Decrease in Trade Payables		4148915		4312388	
Increase / Decrease in other Current Assets		-1384768		3311723	
Increase / Decrease in Other Non Current Assets		-813829		4174104	
Increase/Decrease in Provision		573128		-3918404	
Increase/Decrease in short term Borrowings		-1109248		2143035	
Increase/Decrease in other current liabilities		19656912	31234354	25559452	10849138
Cash Generated from Operations			44606525		64834293
Direct Taxes Paid (Net)		11319430	11319430	14547082	14547082
Net Cash inflow in Operating Activities	Total A		**33287095**	Total A	**50287211**
B. Cash Flow from Investing Activities:					
Purchases of Fixed assets		-3292995		-23741035	
Purchase of Investment		100000		-44205896	
Capital Government Grant of Fixed Assets		0		0	
Loans given to Associates and Subsidiaries		-3700000		-9073304	
Loans given to Others		0		0	
Repayment of Loans given to Associates and Subsidiaries		0		0	
Interest Income		337714		694517	
Gain on Sale of Investment		0		0	
Sale of Investment		0	-6555281	4300000	-72025718
Net Cash used in Investing Activities	Total B		**-6555281**	Total B	**-72025718**

C. Cash Flow from Financing Activities:					
Issue of Equity Capital		0		0	
Share Premium		0		0	
Dividend		0		0	
Issue of Preference Shares		0		0	
Redemption of Preference shares		-5400000		-800000	
Repayment of Borrowing		-7163534		-7440833	
Interest & Finance Charges Paid		-3672562	-16236095	-7544390	-15785223
Net Cash from Financing Activities		**Total C**	**-16236095**	**Total C**	**-15785223**
Net increase /(decrease) in cash and cash equivalents (A+B+C)		**Total (A+B+C)**	**10495718**	**Total (A+B+C)**	**-37523729**
Opening Cash and Cash equivalents			19089795		56613524
Closing Cash and Cash equivalents			**29585513**		**19089795**

Notes :

(i) Figures in brackets represent outflow.

(ii) The above Cash Flow statement has been prepared under the indirect method set out in AS-3 notified under Section 133 of the Companies Act,2013

(iii) Cash and Cash Equivalents represent cash and bank balances.

For MAITREYA MEDICARE LIMITED

MAITREYA MEDICARE LIMITED SURAT

NARENDRA TANWAR
DIN - 0008459007
MD AND CFO
14th Nov 2025, Surat.

Maitreya Medicare Limited
(Formerly known as "Maitreya Medicare Private Limited")
CIN - U24290GJ2019PLC107298
STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE HALF YEAR ENDED SEPTEMBER 30, 2025

Notes to Unaudited standalone financial results

1 The above unaudited Financial Results were reviewed by the Audit Committee and then approved by the Board of Directors in their respective meeting held on November 14, 2025.

2 The Results for the half year and year ended September 30, 2025 are reviewed by the statutory auditor of the company in compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

3 These financial results have been prepared in accordance with the recognition and measurement principles of Accounting Standards ("AS") prescribed section 133 of the Companies Act 2013 (the "Act") read with relevant rules issued thereunder and the other accounting principles generally accepted in India.

4 The figures for the half year ended September 30, 2025 limited reveiwed by the statutory auditors. The management has exercised necessary due diligence to ensure that the said comparative results provide a true and fair view of its affairs.

5 The figures for the half-year ended September 30, 2024 are unaudited published figures in respect of the half-year ended September 30, 2024 limited reveiwed by the statutory auditors. The management has exercised necessary due diligence to ensure that the said comparative results provide a true and fair view of its affairs.

6 The comparative results for the year ended March 31, 2025 have been audited or reviewed by the statutory auditors of the Company. The figures for the year ended March 31, 2024 are audited published figures in respect of the year ended March 31, 2024 audited by the statutory auditors. The management has exercised necessary due diligence to ensure that the said comparative results provide a true and fair view of its affairs.

7 The Company is engaged in the business of providing healthcare services and products. Hence, the Company does not have more than one reportable segment in terms of AS 17 hence segment wise reporting is not applicable.

8 During the year ended March 31, 2024, the company has issued 18,16,000 equity shares of ₹ 10 each at a premium of ₹ 68 - ₹ 72 each by way of initial public offer ("IPO") and got listed on Emerge Platform of National Stock Exchange of India Limited on November 7, 2023.

9 The company has utilised proceeds from IPO as per the object clause of the prospectus as detailed below:

S. No.	Object of the Issue	Allocated Amount (₹ in Thousands)	Amount utilised till September 30, 2025 (₹ in Thousands)	Amount unutilised till September 30, 2025 (₹ in Thousands)	Remarks (if any)

Maitreya Medicare Limited
(Formerly known as "Maitreya Medicare Private Limited")
CIN - U24290GJ2019PLC107298
STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE HALF YEAR ENDED SEPTEMBER 30, 2025

Notes to Unaudited standalone financial results

1	Making investment through Equity in the subsidiary named 'Maitreya Hospital Private Limited' for setting up Hospital at Valsad, Gujarat.	75,000.00	75,000.00	-	Remaining amount is kept with banks.
2	Redemption of part of issued Non-Convertible Redeemable Preference Shares	10,000.00	9,600.00	400.00	
3	Funding the working capital requirements of the company	50,000.00	50,000.00	-	
4	General Corporate Expenses	7,445.60	7,445.60	-	
5	Public Issue Expenses	6,466.40	6,466.40	-	
Total		148,912.00	148,512.00	400.00	

Place : Surat
Date : 14/11/2025

For MAITREYA MEDICARE LIMITED

MAITREYA MEDICARE LIMITED SURAT

NARENDRA TANWAR
DIN - 0008459007
Managing Director & CFO

Saherwala & Co.
CHARTERED ACCOUNTANTS

Member of:
ACURA
& Affiliates
Approved CA Network
Presence in :-
Bengaluru, Delhi, Mumbai, Chennai, Kolkata, Pune, Hyderabad, Patna, Mysuru, Khagaria, Belgavi, Tirupur, Jaipur, Kurnool, **Surat,** Ahmedabad, Vellore & Burdwan

Independent Auditors' Review Report on Half Year and Year To Date Consolidated Unaudited Financial Results of Maitreya Medicare Limited (Formerly Known as Maitreya Medicare Private Limited) pursuant to the Regulation 33 Of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

Review Report
To the Board of Directors of
Maitreya Medicare Limited
(Formerly Known as Maitreya Medicare Private Limited)

1. We have reviewed the accompanying statement of consolidated unaudited financial results of **Maitreya Medicare Limited (Formerly Known as "Maitreya Medicare Private Limited")** (the "Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the Half year ended September 30, 2025 and the year to date results for the period April 1, 2025 to September 30, 2025, ("the Statement ") being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

2. This statement is the responsibility of the Parent's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard 25 Interim Financial Reporting, prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'). Our responsibility is to issue a report on these financial statements based on our review.

3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

SAHERWALA & CO. SURAT Chartered Accountants

4. The Statement includes the results of the following entities:

Maitreya Medicare Limited	Holding Company
Maitreya Lifescience Private Limited	Wholly own Subsidiary
Maitreya Hospital Private Limited	Wholly own Subsidiary
Tulip Agility Private Limited	Subsidiary

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We did not review the interim financial results of 3 subsidiaries as included in the consolidated unaudited financial results, whose interim financial results reflect as follows:

(Rs. In lacs)

Particulars	**For the Half year ended**		**For the year ended**	
	September 30, 2025	**September 30, 2024**	**March 31, 2025**	**March 31, 2024**
Total Revenue	2392.91	2455.26	4723.42	4807.57
Net Profit/(Loss)	-3.61	167.23	181.81	265.64

These interim financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, joint ventures and associates, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

For **Saherwala & Co**
Chartered Accountants
FRN - 108969W

SAHERWALA & CO. SURAT Chartered Accountants

(CA Esmayeel O. Saherwala)
Partner
Membership No. – 122386
UDIN - 25122386BMNXMD5567

Surat, November 14, 2025

MAITREYA MEDICARE LIMITED

(Formerly known as MAITREYA MEDICARE PRIVATE LIMITED)

CONSOLIDATED UNAUDITED BALANCE SHEET AS ON 30th September 2025

CIN No. - U24290GJ2019PTC107298

(Currency: Rs in '000')

Particulars	Note No.	CONSOLIDATED AMOUNT As at 30th September 2025	CONSOLIDATED AMOUNT As at 31st March 2025
I. EQUITY & LIABILITIES			
(1) Shareholders"s Funds			
a) Share capital	1	115523	120923
b) Reserve & Surplus	2	199068	199428
c) Money received against share warrants	3		
d) Minorities Interest / Capital Reserve	3.1	7327	8227
(2) Share application money pending allotment			
(3) Non-Current Liabilities			
a) Long-term Borrowings	4	28180	36348
b)Deffered tax liability (Net)	5	7173	7034
c)Other long term Liabilities			
d)Long term Provisions			
(4) Current Liabilities			
a) Short-term Borrowings	6	14634	15744
b) Trade payables			
(A) total outstanding dues of micro enterprises and small enterprises; and small enterprises.	7	122	3295
(B) total outstanding dues of creditors other than micro enterprises and small enterprises.		41884	28867
c) Other curent Liabilites	8	69323	51805
d) Short term Provisions	9	9001	8272
Total		492236	479943
II. Assets			
(1) Non-current assets			
(a) Property, Plant and Equipment			
(i) Gross Block	10	237470	219621
(ii) Depreciation		74376	67024
(iii) Net Block		163094	152597
b) Non Current Investments	11	10	10
c) Deffered tax asset (net)			
d) Long term loans and advances	12	41569	30489
e) Other Non current assets	13	20296	18442
(2) Current assets			
a) Current Investments	14	422	422
b) Inventories	15	7558	5923
c) Trade receivables	16	144308	149565
d) Cash & Cash equivalents	17	82729	79163
e) Short-term loans and advances	18	27296	39789
f) Other current assets	19	4953	3542
Total		492236	479943

For MAITREYA MEDICARE LIMITED

MAITREYA MEDICARE LIMITED SURAT

NARENDRA TANWAR

DIN - 0008459007

MD AND CFO

14th, November, 2025, Surat

Maitreya Medicare Limited
(Formerly known as "Maitreya Medicare Private Limited")

CIN - U24290GJ2019PLC107298

STATEMENT OF CONSOLIDATED UNAUDITED RESULTS FOR THE HALF YEAR ENDED SEPTEMBER 30, 2025

	Particulars	Half Year ended		For the year ended	
		September 30, 2025	September 30, 2024	March 31, 2025	March 31, 2024
		Unaudited	Unaudited	Audited	Audited
I	Revenue from operations	2,369.93	2,436.28	4,666.20	4,780.35
II	Other income	22.98	18.98	57.22	27.22
III	**Total Revenue (I + II)**	2,392.91	2,455.26	4,723.42	4,807.57
IV	**Expenses:**				
	(a) Cost of Raw Material Consumed	213.65	159.07	287.17	376.69
	(b) Purchase of Stock-in-Trade	257.92	261.90	591.39	561.75
	(c) Changes in inventories of stock-in-trade	4.14	4.66	(2.48)	24.05
	(d) Employee benefits expense	270.57	283.47	612.78	534.84
	(e) Finance costs	42.89	45.10	80.20	84.24
	(f) Depreciation and amortization expense	79.06	66.10	149.64	127.22
	(g) Other expenses	1,519.61	1,408.75	2,689.12	2,711.71
	Total Expenses	2,387.84	2,229.05	4,407.83	4,420.51
V	**Profit before prior-period items and tax (III - IV)**	5.07	226.21	315.59	387.06
VI	**Prior-Period Items**				
VII	**Profit before tax (V- VI)**	5.07	226.21	315.59	387.06
VIII	**Tax expense:**				
	(1) Current tax expense	7.29	57.83	82.72	119.94
	(2) Deferred tax expense/ (credit)	1.39	1.15	0.63	1.48
	(3) Short/ (Excess) provision of tax for earlier years	-	-	50.42	-
		8.68	58.98	133.78	121.42
IX	**Profit from continuing operations (VII-VIII)**	(3.61)	167.23	181.81	265.64
X	**Minority Interest**				
XI	**Profit attributable to owners of the equity (IX-X)**	(3.61)	167.23	181.81	265.64
XII	**Paid-up Equity Share Capital (Face Value of ₹ 10/- each)**	677.60	677.60	677.60	677.60
XIII	**Reserves excluding revaluation reserves as per balance sheet of previous accounting year**				
XIV	**Earnings per Equity Share (Non-Annualised) :-**				
	Face Value of ₹ 10/- each				
	(Pre-bonus)				
	- Basic				
	- Diluted				
	(Post-bonus)				
	- Basic				
	- Diluted				

For MAITREYA MEDICARE LIMITED

MAITREYA MEDICARE LIMITED SURAT

NARENDRA TANWAR
DIN - 00084590O7
Managing Director & CFO

Place : Surat
Date : 14/11/2025

MAITREYA MEDICARE LIMITED
(Formerly known as MAITREYA MEDICARE PRIVATE LIMITED)
Statement of Consolidated Un Audited Profit & Loss for the year ended 30th September 2025
CIN No. - U24290GJ2019PTC107298
(Currency: Rs in '000')

Particulars	Note No.	CONSOLIDATED AMOUNT As at 30th September 2025	CONSOLIDATED AMOUNT As at 31st March 2025
I. Revenue from operations	20	236993	466620
II. Other Income	21	2298	5722
III. Total Revenue (I+II)		239291	472342
IV. Expenses:			
Cost of materials consumed	22	21365	28717
Purchase of stock-in-Trade	23	25792	59139
Changes in inventories of finished goods, work-in-progress and stock-in-Trade	24	414	-248
Employee benefit expense	25	27057	61278
Financial Costs	26	4289	8020
Depreciation and amortization expense	27	7906	14964
Other expense	28	151961	268912
Total Expense		238784	440783
V.Profit Before exceptional and extradinary items and tax	(III-IV)	508	31559
VI. Exceptional Items			
Adjustment of GST Liability			
Reversal of Previous Year Income Tax/TCS			
Rectification of Previous Year Mutual Fund Value			
Rectification of Depreciation			
Gratuity Prior Period			
Operating lease Prior Period Adjustment			
VII. Profit Before extraorinary items and tax (V-VI)		508	31559
VIII. Extraordinary Items			
IX. Profit before tax (VII-VIII)		508	31559
X. Tax expense:			
(1) Current Tax	29	729	8272
(2) Deferred Tax	30	139	63
(3) MAT Credit Entitlement			
(4) Incpme Tax Paid 2023-2024			5042
XI. Profit(Loss) from the period from continuing operations		-360	18181
XII. Profit/(Loss) from discontinuing operations			
XIII. Tax expense of discontinuing operations			
XIV. Profit/(Loss) from discountinuing operations (XII- XIII)			
XV. Profit/Loss for the period (XI+XIV)		-360	18181
XVI. Earning per equity share:	31		
Basic		(0.05)	2.76
Diluted		(0.05)	2.76

For MAITREYA MEDICARE LIMITED

MAITREYA MEDICARE LIMITED * SURAT

NARENDRA TANWAR
DIN - 0008459007
MD AND CFO
14th, November, 2025, Surat

MAITREYA MEDICARE LIMITED
(Formerly known as MAITREYA MEDICARE PRIVATE LIMITED)
Statement of Consolidated Un Audited Cash Flow Statement for the year ended 30th September 2025
CIN No. - U24290GJ2019PTC107298
(Currency: Rs in '000')

PARTICULARS		CONSOLIDATED AMOUNT As at 30th September 2025	CONSOLIDATED AMOUNT As at 31st March 2025
A. Cash Flow from Operating Activities:			
Net Profit before tax		508	32102
Adjustments for :			
Depreciation		7906	14421
Interest Income		-1159	-2154
Interest & Finance Charges Paid		4266	7984
Gratuity		440	1677
Profit on sale of Investment			225
Sundry Balance Write back		244	
	Sub Total	11697	22153
Operating Profit before Working Capital Changes		12205	54255
Adjustments for :			
Increase / Decrease in Inventories		-1635	147
Increase / Decrease in Short-term loans and advances		824	-3478
Increase / Decrease in Trade Receivables		16994	-18444
Increase / Decrease in Trade Payables		-2136	6571
Increase / Decrease in Other Current Assets		9365	-619
Increase / Decrease in Other Non Current Assets		-794	4174
Increase / Decrease in Long-term loans and advances		-1500	145
Increase/Decrease in Provision		556	-3918
Increase/Decrease in short term liabilites		-1109	2143
Increase/Decrease in Current Liability		18249	24289
	Sub Total	38813	11009
Cash Generated from Operations		51018	65264
Direct Taxes Paid (Net)		11475	14695
Net Cash inflow in Operating Activities	**Total A**	39543	50568
B. Cash Flow from Investing Activities:			
Purchases of Property, Plant and Equipment		-18403	-23813
Purchase of Investment		100	-44656
Other Bank Balance			
Capital Government Grant of Property, Plant and Equipment			
Loans given to Associates and Subsidiaries		-3700	-9073
Loans given to Others			
Loans received from Holding compnay			-2621
Interest Income		1159	2154
Gain on Sale of Investment			
Sale of Investment			4300
		-20844	-73709
Net Cash used in Investing Activities	**Total B**	-20844	-73709
C. Cash Flow from Financing Activities:			
Issue of Equity Capital			
Share application Money received		-100	51600
Share Premium			
Dividend			
Proceed of Borrowing		2696	4783
issue of Preference Shares			
Redemption of Preference shares		-6300	-2000
Repayment of Borrowing		-7164	-9665
Interest & Finance Charges Paid		-4264	-7984
		-15132	36735
Net Cash from Financing Activities	**Total C**	-15132	36735
Net increase /(decrease) in cash and cash equivalents (A+B+C)		3567	13594
Opening Cash and Cash equivalents		79164	65569
Closing Cash and Cash equivalents		82730	79163

Notes :
(i) Figures in brackets represent outflow.
(ii) The above Cash Flow statement has been prepared under the indirect method set out in AS-3 notified under Section 133 of the Companies Act,2013
(iii) Cash and Cash Equivalents represent cash and bank balances.

For MAITREYA MEDICARE LIMITED

MAITREYA MEDICARE LIMITED SURAT

NARENDRA TANWAR
DIN - 00084159007
MD AND CFO
14th, November, 2025, Surat

Maitreya Medicare Limited
(Formerly known as "Maitreya Medicare Private Limited")
CIN - U24290GJ2019PLC107298
STATEMENT OF CONSOLIDATED UNAUDITED RESULTS FOR THE HALF YEAR ENDED SEPTEMBER 30, 2025

Notes to Unaudited consolidated financial results

1 The above unaudited Financial Results were reviewed by the Audit Committee and then approved by the Board of Directors in their respective meeting held on November 14, 2025.

2 The Results for the half year and year ended September 30, 2025 are reviewed by the statutory auditor of the company in compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

3 The results includes results of 2 wholly owned subsidiaries - Maitreya Hospital Private Limited and Maitreya Lifescience Private Limited and 1 subsidiary - Tulip Agility Private Limited.

4 These financial results have been prepared in accordance with the recognition and measurement principles of Accounting Standards ("AS") prescribed section 133 of the Companies Act 2013 (the "Act") read with relevant rules issued thereunder and the other accounting principles generally accepted in India.

5 The figures for the half year ended September 30, 2025 limited reveiwed by the statutory auditors. The management has exercised necessary due diligence to ensure that the said comparative results provide a true and fair view of its affairs.

6 The figures for the half-year ended September 30, 2024 are unaudited published figures in respect of the half-year ended September 30, 2024 limited reveiwed by the statutory auditors. The management has exercised necessary due diligence to ensure that the said comparative results provide a true and fair view of its affairs.

7 The comparative results for the year ended March 31, 2025 have been audited or reviewed by the statutory auditors of the Company. The figures for the year ended March 31, 2024 are audited published figures in respect of the year ended March 31, 2024 audited by the statutory auditors. The management has exercised necessary due diligence to ensure that the said comparative results provide a true and fair view of its affairs.

8 The Company is engaged in the business of providing healthcare services and products. Hence, the Company does not have more than one reportable segment in terms of AS 17 hence segment wise reporting is not applicable.

9 During the preceding year ended March 31, 2024, the company has issued 18,16,000 equity shares of ₹ 10 each at a premium of ₹ 68 - ₹ 72 each by way of initial public offer ("IPO") and got listed on Emerge Platform of National Stock Exchange of India Limited on November 7, 2023.

Maitreya Medicare Limited
(Formerly known as "Maitreya Medicare Private Limited")
CIN - U24290GJ2019PLC107298
STATEMENT OF CONSOLIDATED UNAUDITED RESULTS FOR THE HALF YEAR ENDED SEPTEMBER 30, 2025

Notes to Unaudited consolidated financial results

10 The company has utilised proceeds from IPO as per the object clause of the prospectus as detailed below:

S. No.	Object of the Issue	Allocated Amount (₹ in Thousands)	Amount utilised till September 30, 2025 (₹ in Thousands)	Amount unutilised till September 30, 2025 (₹ in Thousands)	Remarks (if any)
1	Making investment through Equity in the subsidiary named 'Maitreya Hospital Private Limited' for setting up Hospital at Valsad, Gujarat.	75,000.00	75,000.00	-	Remaining amount is kept with banks.
2	Redemption of part of issued Non-Convertible Redeemable Preference Shares	10,000.00	9,600.00	400.00	
3	Funding the working capital requirements of the company	50,000.00	50,000.00	-	
4	General Corporate Expenses	7,445.60	7,445.60	-	
5	Public Issue Expenses	6,466.40	6,466.40	-	
Total		148,912.00	148,512.00	400.00	

For MAITREYA MEDICARE LIMITED

Place : Surat
Date : 14/11/2025

MAITREYA MEDICARE LIMITED SURAT

NARENDRA TANWAR
DIN - 0008459007
Managing Director & CFO